Feed - Buzzberg

12:30
Jul 30 ◎

CI FY2026 Q2 Watch

The Cigna Group (CI) FY2026 Q2 Earnings Call

LLY NVO CI ▾

Brian Evanko

Moderating GLP-1 growth rates with slight decline in coverage levels; Cigna omitted GLP-1 weight loss drugs from its own employee plan citing affordability. — Signals potential top-line pressure for GLP-1 manufacturers if large employers follow suit; however, this is offset by the specialty business outperformance.

"We did make the difficult decision during 2026 to discontinue financial support for GLP-1 drugs for weight management within our own employee health plan."

LLY WATCH NVO WATCH

Brian Evanko

Management raised full-year EPS guidance citing strong first half performance and confidence in durable growth, though tempered by a 'prudent view' of the environment and intentions to reinvest.

"With our momentum, we're confident that we'll deliver on our increased adjusted EPS outlook of at least $30.45 for 2026."

CI WATCH

HIGH

12:30
Apr 30 ◎

CI FY2026 Q1 Watch

The Cigna Group (CI) FY2026 Q1 Earnings Call

CI ▾

David Cordani

Management is raising full-year guidance due to strong first-quarter performance, particularly in specialty care and pharmacy, indicating a confident outlook for the rest of the year.

"With our performance, we are raising our full year 2026 adjusted EPS outlook to at least $30.35"

CI WATCH

HIGH

13:30
Feb 05 ◎

CI FY2025 Q4 Watch

The Cigna Group (CI) FY2025 Q4 Earnings Call

SHLD PGNY HSPC FTC MKI ▾

David Cordani

Cigna highlights Shields as a key investment expanding its specialty pharmacy reach into hospitals, implying growth and strategic value for Shields.

"we further expanded our specialty capabilities to serve hospitals and health systems, in part with our new investment in Shields Health Solutions"

SHLD WATCH

Brian Avenko

Cigna partners with fertility benefits providers Progeny and Carrot, affirming their market traction and role in expanding employer fertility coverage.

"we collaborated with Progeny and Carrot to offer new coverage options for employers to support patients through their fertility journeys"

PGNY WATCH

Brian Avenko

Cigna's collaboration with Headspace expands the latter's reach into commercial insurance memberships, reinforcing its B2B2C model.

"we announced an industry-first collaboration with Headspace to support the mental health of millions of Cigna healthcare customers with exclusive digital features and content"

HSPC WATCH

David Cordani

The resolution of the FTC matter removes regulatory overhang for Cigna's PBM operations, creating a clearer operating environment.

"The settlement is a comprehensive resolution of all matters brought by the FTC regarding pharmacy benefits business"

FTC WATCH

David Cordani

Evernorth's role as pharmacy partner for EMD Serono's fertility treatment via TrumpRx highlights a direct commercial relationship.

"when the new TrumpRx site launches, Evernorth is the pharmacy partner to the site and will dispense EMD Serrano treatment for fertility"

MKI WATCH

Brian Avenko

Carrot Fertility is another new partner in Cigna's fertility benefits expansion, likely benefiting from increased membership access.

"we collaborated with Progeny and Carrot to offer new coverage options for employers to support patients through their fertility journeys"

CRT WATCH

David Cordani

Management guides to at least 1.4% EPS growth in 2026, maintaining its long-term 10-14% growth algorithm despite PBM model investments and FTC-related transition. The tone is confident and proactive, emphasizing a clear model for navigating regulatory changes.

"We are confident in our ability to deliver full-year 2026 adjusted earnings of at least $30.25 per share and our ability to deliver attractive long-term EPS growth."

CI WATCH

Brian Avenko

Biosimilar momentum is a major driver. Humira biosimilar penetration is now the vast majority of eligible scripts, with plans for $0 out-of-pocket on Stelara biosimilars. — Confirms the rapid conversion to biosimilars, which will pressure originator brands but provide savings that Cigna can use to offset its own margin pressures.

"the Humira penetration in 2025 ended up representing the vast majority of eligible scripts"

ABBV WATCH AMGN WATCH SNDK WATCH

HIGH

Feed — Buzzberg